Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00569582 · OUTCOME

Decrease in Diastolic Blood Pressure.

A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome · Source last updated 2013-08-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
Baseline to Week 24

What was measured

Responder is defined as subject with a decrease greater than or equal to 5mm Hg in diastolic blood pressure from baseline to week 24 or last visit.

Groups in this outcome

Mifepristone

Mifepristone was administered at doses of 300-1200 mg daily.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Mifepristone21

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Mifepristone8Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        8
denoms
  1. counts
    1. group Id
      OG000
      value
      21
    units
    Participants
description
Responder is defined as subject with a decrease greater than or equal to 5mm Hg in diastolic blood pressure from baseline to week 24 or last visit.
groups
  1. description
    Mifepristone was administered at doses of 300-1200 mg daily.
    id
    OG000
    title
    Mifepristone
param Type
NUMBER
reporting Status
POSTED
time Frame
Baseline to Week 24
title
Decrease in Diastolic Blood Pressure.
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice